Patents by Inventor Rongbo CAO

Rongbo CAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240391971
    Abstract: A fusion protein comprises an Fc variant and a GDF15 active domain, wherein the Fc variant has amino acid substitutions at position 356 and/or position 439 of the IgG Fc according to EU numbering and still has the ability to form homodimer. By fusing the Fc variant with the GDF15 active domain, the Fc-GDF15 fusion protein has significantly improved physicochemical properties and recombinant expression levels, has in vitro activity equivalent to or better than natural GDF15 molecules, and has significantly prolonged in vivo circulating half-life, which can support the dosing frequency of once every two weeks or even once a month.
    Type: Application
    Filed: August 23, 2022
    Publication date: November 28, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jiangyu YAN, Rongbo CAO, Lin XIAO, Junnan ZENG, Limei HUANG, Xiling WEI, Zhaofeng LI, Qingwei GONG, Xingguo YAN, Jing LI, Danxia HUANG, Xiaofeng CHEN, Wenjia LI
  • Publication number: 20240350588
    Abstract: A GDF15 fusion protein and a method for treating obesity using same. The fusion protein includes an Fc variant and a GDF15 active domain, wherein the Fc variant has an amino acid substitution at position 356 and/or position 439 of the IgG Fc according to EU numbering and still has the ability to form a homodimer. By means of fusing the Fc variant with the GDF15 active domain, the Fc-GDF15 fusion protein has significantly improved physical and chemical properties and recombinant expression level, has an in vitro activity comparable to or better than that of a natural GDF15 molecule, and has a significantly prolonged in vivo cyclic half-life, which may support the dosing frequency once every two weeks or even once a month.
    Type: Application
    Filed: August 23, 2022
    Publication date: October 24, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jiangyu YAN, Rongbo CAO, Lin XIAO, Junnan ZENG, Limei HUANG, Xiling WEI, Zhaofeng LI, Qingwei GONG, Xingguo YAN, Jing LI, Danxia HUANG, Xiaofeng CHEN, Wenjia LI
  • Publication number: 20240343770
    Abstract: GDF15 fusion proteins and uses thereof, the fusion protein includes an Fc variant and a GDF15 active domain, wherein the Fc variant has amino acid substitutions at position 356 and/or position 439 of the IgG Fc according to EU numbering and still has the ability to form homodimer. By fusing the Fc variant with the GDF15 active domain, the Fc-GDF15 fusion protein has significantly improved physicochemical properties and recombinant expression levels, has in vitro activity equivalent to or better than natural GDF15 molecules, and has significantly prolonged in vivo circulating half-life, which can support the dosing frequency of once every two weeks or even once a month.
    Type: Application
    Filed: August 23, 2022
    Publication date: October 17, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jiangyu YAN, Rongbo CAO, Lin XIAO, Junnan ZENG, Limei HUANG, Xiling WEI, Zhaofeng LI, Qingwie GONG, Xingguo YAN, Jing LI, Danxia HUANG, Xiaofeng CHEN, Wenjia LI